| This week's sponsor is Premier Research. | | | Overcoming Risk in Oncology Drug Development
Oncology drug development is fraught with obstacles and risks, and you must carefully plan each step. Click here for tips on finding the fast track. Premier Research. It's what we do. Best. |
Today's Rundown FibroGen sinks as roxadustat safety results confuse investors Bayer puts up $150M to build West Coast cell culture facility Looking beyond cancer, Twentyeight-Seven Therapeutics bumps up series A to $82M+ Harvard-born diabetes startup Semma reports advances in turning stem cells into insulin producers EuroBiotech Report—Lundbeck, Pfizer ink deals; Confo, Promethera raise cash; and Bicycle FiercePharmaAsia—Takeda-Novartis Xiidra deal; Daiichi-AZ's HER2 ADC; Sun Pharma eyes China Chutes & Ladders—Eisai installs new Alzheimer's leadership team Featured Story | | | Friday, May 10, 2019 FibroGen has reported top-line results from a pooled analysis of its phase 3 roxadustat safety data. Shares in FibroGen plummeted following the readout as the wording of the number-free statement and subsequent conference call raised concerns about the safety of the kidney disease drug. |
|
|
Top Stories Friday, May 10, 2019 Bayer is investing $150 million to build a cell culture facility in California. The 40,000-square-foot site will support Bayer’s pipeline of oncology and cardiology programs when it comes online late in 2021. Friday, May 10, 2019 With a series A extension of $17.75 million, Twentyeight-Seven will ramp up its cancer programs, develop programs aimed at other types of RNA and apply its work in disease areas other than cancer. Friday, May 10, 2019 Semma Therapeutics has faced an obstacle with its process of turning undifferentiated pluripotent stem cells into insulin-producing pancreatic beta cells: Only 30% of the resulting cells turn out to be beta cells. Now, a Semma-Harvard University team has figured out how to boost the proportion of beta cells emerging from their process to 80%. Thursday, May 9, 2019 In this week's EuroBiotech Report, Lundbeck and Pfizer strike buyouts, Confo and Promethera raise cash and Bicycle hires staff. Friday, May 10, 2019 Takeda sells dry-eye drug Xiidra to Novartis and offloads TachoSil patch to Johnson & Johnson. Daiichi Sankyo's HER2 antibody-drug conjugate, shared with AstraZeneca, meets its goal in a pivotal trial. Sun Pharma scouts for a partner to expand into China. And more. Friday, May 10, 2019 Eisai installs new Alzheimer's clinical trial leadership team; Insys founder found guilty in landmark opioid lawsuit; and Gilead's chief plots Kite CEO hire, plus organizational tweaks. Those moves plus more hirings, firings and retirings throughout the industry. Resources Sponsored by: Catalent Download the executive summary to learn key considerations for a successful technology transfer for manufacturing drug products, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Patheon, part of Thermo Fisher Scientific Choosing the Best Sterile Dosage Form for Your Phase I Clinical Supply Needs. Sponsored by: Patheon, part of Thermo Fisher Scientific Designed with speed & flexibility,Quick to Clinic™ for Oral Solid Dose helps deliver products to Phase I Clinic in as little as 14 weeks. Sponsored by: AlphaSense What is agile competitive intelligence, and how can help healthcare researchers stay ahead of the curve? Sponsored by: JPEO-CBRND – Medical Countermeasure Systems MCS is currently seeking broad-based industry/academia collaboration on research and prototype work in technical areas related to developing medical countermeasures for the Joint Warfighter. Sponsored by: Outer Edge Technology Learn how the cloud can support the performance and security requirements for validated, mission-critical applications historically designed and implemented exclusively via on-premises deployment. Sponsored by: Elemental Machines Learn how cloud-connected IoT sensors are transforming operations in leading life science labs. Read our white paper “The Smart Lab”. Presented by: Total Brain Total Brain Announces Personalized Test for Treatment Prediction in Depression with 80% Accuracy. Sponsored by: Veradigm Prescription price transparency technology is here – but is it making a difference? Find out HERE. Sponsored by: Strativity Every life sciences firm talks about patient-centricity, but are you doing what it takes to deliver? Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. Drug Development Immersion May 16-17, 2019 | Boston, MA 2019 BIO International Convention June 3-6, 2019 | Philadelphia, PA FierceBiotech Executive Breakfast at BIO 2019 – Getting Real: The Changing Tide on Real-World Evidence in Drug Development June 5, 2019 | Philadelphia, PA World Pharma Week June 17-20, 2019 | Seaport World Trade Center | Boston, MA Medical Sensors Design Conference June 25, 2019 | McEnery Convention Center | San Jose, CA Sensors Expo & Conference June 25-27, 2019 | McEnery Convention Center | San Jose, CA 5th Annual CAR-TCR Summit September 10-13, 2019 | Boston, MA, USA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! | 